Open Access

Diprophylline inhibits non‑small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway

  • Authors:
    • Hong‑Ying Zhao
    • Yun‑Hui Ren
    • Xiu‑Bao Ren
    • Yu Wang
  • View Affiliations

  • Published online on: November 8, 2018     https://doi.org/10.3892/ol.2018.9678
  • Pages: 857-862
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diprophylline (DPL) is identified as a methylxanthine (MX) derivative. A number of MX derivatives are reported to have anti‑tumor effects. However, it is not clear whether DPL has a therapeutic effect on non‑small cell lung cancer (NSCLC). The aim of the present study was to investigate the effects of DPL on NSCLC and to elucidate the potential underlying mechanism. A Cell Counting Kit‑8 assay was used to evaluate the potential effect of DPL on A549 cell proliferation. Transwell invasion and migration assays were performed to assess the effect of DPL on A549 cell migration and invasion. Furthermore, the percentage of apoptotic cells was detected by flow cytometric analysis, and proteins associated with apoptosis, including apoptosis regulator Bcl‑2, apoptosis regulator BAX and active caspase‑3, were examined by western blotting. Finally, the expression levels of molecules relevant to phosphoinositide 3‑kinase (PI3K) signaling were detected by western blot analysis. The present study demonstrated that DPL may significantly inhibit A549 cell proliferation, migration and invasion. Furthermore, treatment with DPL may significantly induce A549 cell apoptosis. Finally, the protein expression levels associated with the PI3K signaling pathway were significantly inhibited in A549 cells following treatment with DPL. In conclusion, DPL may inhibit the proliferation and migration of NSCLC by inactivating the PI3K signaling pathway, and DPL is a promising novel therapeutic drug for NSCLC.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao HY, Ren YH, Ren XB and Wang Y: Diprophylline inhibits non‑small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway. Oncol Lett 17: 857-862, 2019
APA
Zhao, H., Ren, Y., Ren, X., & Wang, Y. (2019). Diprophylline inhibits non‑small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway. Oncology Letters, 17, 857-862. https://doi.org/10.3892/ol.2018.9678
MLA
Zhao, H., Ren, Y., Ren, X., Wang, Y."Diprophylline inhibits non‑small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway". Oncology Letters 17.1 (2019): 857-862.
Chicago
Zhao, H., Ren, Y., Ren, X., Wang, Y."Diprophylline inhibits non‑small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway". Oncology Letters 17, no. 1 (2019): 857-862. https://doi.org/10.3892/ol.2018.9678